Strong R&D Commitment to Mental Illness

Strong R&D Commitment to Mental Illness

05.02.13 | By

It was suggested yesterday that drug companies aren’t putting enough resources into developing medicines for mental illness.  This couldn’t be further from the truth.   The reality is that as an industry, we are deeply vested in finding new treatments for patients suffering from debilitating neurological and mental health illnesses. 

Earlier this year, we released a biopharmaceutical pipeline report highlighting the fact that there are 610 medicines in development worldwide for neurological diseases (such as Alzheimer’s and Parkinson’s disease) and 240 potential medicines in the psychiatry space.  The report also unveiled the fact that the percentage of medicines in development that are potential first-in-class – medicines that can help patients with serious unmet medical needs – is particularly high in neurology (84 percent) and psychiatry (79 percent). 

If this doesn’t demonstrate our strong commitment in finding new treatments for mental illness, then I don’t know what will.

As John Castellani recently noted in an oped in The Hill, a collaborative approach is needed to defeat devastating and complex diseases such as Alzheimer’s and that innovation partnerships between academia, biopharmaceutical companies, patient advocacy organizations and federal research institutions are becoming increasingly important to help move the research forward.  After all, medical research isn’t a solo act; it is a team mission. 

This is something we must all keep in mind as we continue to find solutions to some of the greatest health care challenges before us today and tomorrow. 

I hope this helps clears up any confusion on this matter. 


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context